476060 - Onconic Therapeutics, Inc.

476060 Summary
Biopharma
Stock Price & Overview
₩16,440 -670 (-3.92%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩16,440  ≈ US$12  ·  Market cap ₩0.7tn (≈ $533m)

Material matter affecting investment judgment (clinical trial plan amendment approved)

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항(임상시험계획변경승인) (자큐보정(JP1366)(자스타프라잔시트르산염) 기반 삼제요법의 헬리코박터 파일로리 양성 환자 대상 유효성 및 안전성 평가를 위한 제3상 임상시험계획승인(변경승인))